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Abstract 
Background: Percent mammographic density (PD) estimates the proportion of stromal, fat, and epithelial breast tis‑
sues on the mammogram image. Adjusted for age and body mass index (BMI), PD is one of the strongest risk factors 
for breast cancer [1]. Inherited factors are hypothesized to explain between 30 and 60% of the variance in this trait 
[2–5]. However, previously identified common genetic variants account for less than 6% of the variance in PD, leaving 
much of the genetic contribution to this trait unexplained. We performed the first study to examine whether germline 
copy number variation (CNV) are associated with PD. Two genome‑wide association studies (GWAS) of percent den‑
sity conducted on the Illumina 660W‑Quad were used to identify and replicate the association between candidate 
CNVs and PD: the Minnesota Breast Cancer Family Study (MBCFS) and controls from the Mayo Venous Thromboembo‑
lism (Mayo VTE) Case–Control Study, with 585 and 328 women, respectively. Linear models were utilized to examine 
the association of each probe with PD, adjusted for age, menopausal status and BMI. Segmentation was subsequently 
performed on the probe‑level test statistics to identify candidate CNV regions that were associated with PD.
Results: Sixty‑one probes from five chromosomal regions [3q26.1 (2 regions), 8q24.22, 11p15.3, and 17q22] were 
significantly associated with PD in MBCFS (p‑values <0.0001). A CNV at 3q26.1 showed the greatest evidence for asso‑
ciation with PD; a region without any known SNPs. Conversely, the CNV at 17q22 was largely due to the association 
between SNPs and PD in the region. SNPs in the 8q24.22 region have been shown to be associated with risk of many 
cancers; however, SNPs in this region were not responsible for the observed CNV association. While we were unable 
to replicate the associations with PD, two of the five CNVs (3q26.1 and 11p15.3) were also observed in the Mayo VTE 
controls.
Conclusions: CNVs may help to explain some of the variability in PD that is currently unexplained by SNPs. While 
we were able to replicate the existence of two CNVs across the two GWAS studies, we were unable to replicate the 
associations with PD. Even so, the proximity of the identified CNV regions to loci known to be associated with breast 
cancer risk suggests further investigation and potentially shared genetic mechanisms underlying the PD and breast 
cancer association.
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Background
Percent mammographic density (PD) is an estimate of 
the proportion of stromal and epithelial breast tissues 
on the mammogram image. Adjusted for age and body 
mass index (BMI), PD is one of the strongest risk factors 
for breast cancer, and women in the highest quartile of 
density have a 3- to 5-fold increased risk compared to 
women in the lowest quartile [1]. Twin and family studies 
have shown that PD is highly heritable and that inherited 
factors are estimated to explain between 30 and 60% of 
the variance in this trait [2–5]. To date, several genetic 
loci or single nucleotide polymorphisms (SNPs) have 
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been identified to be associated with percent density 
using genome-wide association studies (GWAS), includ-
ing a novel locus on chromosome 12q24 and established 
breast cancer loci, ZNF365, ESR1, LSP1 and RAD51L1, 
suggesting shared heritability between PD and breast 
cancer [6–8]. However, together these SNPs are esti-
mated to account for less than 6% of the variance in PD, 
leaving much of the genetic contribution to this trait 
unexplained.
Like SNPs, the deletion or amplification of segments 
of DNA, known as copy number variation (CNV), are 
common in the germline and have been implicated 
in the risk of diseases including neuroblastoma, cata-
racts, and cancer [9–13]. In fact, CNVs are estimated to 
account for 13% of the human genome [9, 14, 15]. While 
the mechanisms underlying the development of CNVs 
remain generally unknown, it has been shown that CNVs 
are frequently located near telomeres, centromeres, and 
proximal duplicated regions [9, 16, 17]. Furthermore, rare 
germline genomic duplications and deletions have been 
shown to disrupt high-penetrance tumor suppressor 
genes, such as the BRCA1 and BRCA2 genes, in breast 
cancer patients, and have been demonstrated to aggre-
gate within families [18–20]. Several recent publications 
have linked germline copy number variation (CNV) in 
other regions of the genome, including both inter- and 
intra-genic regions, with risk or recurrence of breast can-
cer [21–24].
As PD has been shown to be highly heritable, we 
hypothesized that some of the variance not explained by 
associated SNPs could be due to germline CNVs. CNVs 
have been shown to have adequate coverage on current 
SNP arrays, at least for large and intermediate size CNVs 
(CNVs >5 kb) [17], and the size of identified deletions and 
amplifications in most of the prior studies with cancer 
ranged from intermediate (4 kb) to large (2 Mb). There-
fore, using data from two independent GWAS studies, we 




Two independent studies contributed copy number and 
PD phenotype information. The protocol was approved 
by the Mayo Clinic Institutional Review Board. The first 
stage utilized 595 women of white European ancestry 
with GWAS and PD data from the Minnesota Breast 
Cancer Family Study (MBCFS) [6, 25, 26]. Briefly, females 
from 89 multigenerational families ascertained through a 
breast cancer proband diagnosed between 1944 and 1952 
and who provided the location and consent to retrieve 
their mammograms were recruited to a family study of 
breast density. Among the 737 age-eligible women (over 
age 40) we retrieved the mammograms of 658 (89%). Of 
these, 595 women had DNA available for GWAS analyses 
[6].
The replication stage consisted of 336 women who 
were female controls within the Mayo Venous Throm-
boembolism Case–Control Study (Mayo VTE) [6, 27]. 
Clinic-based controls were prospectively selected from 
persons undergoing outpatient general medical exami-
nations from 2004 to 2009 who had no previous diagno-
sis of VTE or superficial vein thrombosis, active cancer, 
antiphospholipid antibody syndrome, rheumatologic or 
other autoimmune disorder, or prior bone marrow or 
liver transplant.
Both populations were genotyped on the Illumina 
660W-Quad genotyping platform, which provided infor-
mation on 657,172 autosomal probes for the evaluation 
of CNVs.
For both studies, the mammogram closest to enroll-
ment date was obtained and digitized on either a Lumis-
can 75 scanner (MBCFS) or Array 2905HD Laser Film 
Digitizer (Mayo VTE). PD was estimated by the same 
programmer (FFW) using a computer-assisted thresh-
olding program Cumulus [28]. For MBCFS, percent 
density from the mediolateral oblique and craniocaudal 
views were averaged and used as the primary phenotype 
and for Mayo VTE, only the left craniocaudal view was 
used. We have previously shown concordance of den-
sity from both breast sides and views [4]. Although both 
studies had high intrareader reliability (>0.9 for both), 
we acknowledge the lower PD in the Mayo VTE popula-
tion that is partly due to the increased age and BMI of 
the women relative to MBCFS, but also due to drift in 
the PD measure with time. There were 5 years between 
evaluations of PD for these two studies. However, these 
two studies both identified significant associations with a 
SNP at chromosome 12 [6] and show similar associations 
with clinical characteristics (data not shown).
Statistical analysis
Log R ratio (LRR) data were extracted from the two 
GWAS using Genome Studio. The LRR data for each 
probe were median normalized per plate so that the dis-
tributions of LRR values were similar across all plates 
[29, 30]. PennCNV was used to extract quality-control 
metrics and samples were removed from further analysis 
if the standard deviation of the LRR >0.35, the B-Allele 
Frequency (BAF) drift was >0.0015, the wave factor was 
>0.05, or the number of CNV intervals was >500 [31].
The primary goal of the analysis was to identify copy 
number regions associated with PD. To do so, we first 
utilized the probe level data and performed probe-spe-
cific tests using linear mixed effects models for MBCFS 
(to account for the family design) and linear models for 
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Mayo VTE (Flow diagram,  Additional file  1) [32]. The 
square-root of PD was the dependent variable and probe-
specific LRR values, age, inverse of body mass index 
(BMI) and menopausal status were included as inde-
pendent variables. Second, we identified candidate copy 
number regions of interest by applying circular binary 
segmentation (CBS) to the absolute value of the probe-
specific test statistics [33]. The absolute values of the 
probe-specific test statistics were averaged within each 
segment. Segments defined by three or more probes with 
a mean test statistic greater than one were considered 
for further analysis. Third, we conservatively expanded 
the segments by including six times the initial number of 
probes in the CBS identified segment both prior to the 
start of the segment and after the end of the segment. 
For example, if a segment contained ten probes, then 
the expanded region would add 60 probes to the start 
and an additional 60 probes to the end of the segment 
for a total size of 130 probes. Empirically this appeared 
to be a sufficient expanded region so as to not impact 
the identification of the segment of interest. Fourth, we 
applied permutation tests to each expanded region using 
10,000 iterations. For each iteration the phenotype was 
permuted, the probe-specific association models (mixed 
effect model for MBCFS and linear model for Mayo VTE) 
were run, and the CBS algorithm was applied. The probe-
specific test statistics for all probes within the CBS iden-
tified region were averaged and the region was assigned 
the mean value. For identified regions that included a 
significant SNP, the above modeling process was repeated 
including the most significant SNP and the LRR value.
P values were computed from the permutation tests 
and were based on how many times the observed, non-
permuted test statistic, exceeded all of the permuted runs 
(p value = N/10,001). If there were no permuted observa-
tions greater than the observed value, then the probe was 
assigned the value 1/10,001. Any given probe was consid-
ered to be significantly associated with breast density if 
the permuted P < 1/10,000. For the replication analysis, a 
significance level of 0.05 was used.
Recent projections suggest that CNVs may account for 
13% of the human genome and their occurrences have 
been cataloged in public databases such as the Toronto 
Database of Genomic Variants and the Genome Struc-
tural Variation Consortium CNV discovery project [9, 14, 
15]. As a secondary analysis, we evaluated whether any 
of our primary identified regions were in this database. 
We then used the validation-calling algorithm within 
PennCNV, which is designed to call CNVs in known 
common CNV regions by using all the probes within a 
defined region and identifying the most likely copy num-
ber (0, 1, 2, 3 and 4) [31]. Association analyses (mixed 
effect model for MBCFS and linear model for Mayo VTE) 
were run to test the association of common CNVs with 
PD.
Each SNP (coded as 0, 1, or 2) was also evaluated using 
a linear model (linear mixed effects model for MBCFS) 
where the square-root of PD was the dependent variable 
and SNP, age, inverse of body mass index (BMI) and men-
opausal status were included as independent variables.
Results
The evaluation of the log R ratio (LRR) standard devia-
tion, B-allele frequency (BAF) drift and wave factor for 
the 595 members of the Minnesota Breast Cancer Fam-
ily Study (MBCFS) resulted in exclusion of ten subjects 
(Additional file  2). Thus, 585 patients were analyzed to 
identify associations between CNV and PD, adjusted for 
age, BMI and menopausal status. PD was lower in the 
Mayo VTE population, partly due to the slightly older age 
and higher BMI, but also due to drift in the PD measure 
can occur with time (Table 1).
Analysis of the 657,172 autosomal chromosome probes 
from the Illumina 660W Quad identified five regions 
on four chromosomes [3q26.1 (contained two regions), 
8q24.22, 11p15.3, and 17q22] to be significantly associ-
ated with PD after adjusting for age, menopausal status, 
and BMI in MBCFS (Table 2). Candidate regions identi-
fied in the initial data reduction analysis step are shown 
in Additional file 3. Figure 1 shows the probe-level p-val-
ues, SNP p-values, recombination rates, and neighbor-
ing genes for each of the four chromosomes. Figure 2a–d 
shows the LRR values for each of the four chromosomes. 
The two 3q26.1 regions consisted of a total of 30 probes 
that were significantly associated with PD in MBCFS and 
were clustered in a region without SNPs on the Illumina 
660W platform (Figure 1a). Our algorithm detected two 
Table 1 Characteristics of  subjects used in  the discovery 
and replication phases
MBCFS Mayo Breast Cancer Family Study and Mayo VTE venous thrombo-
embolism Case–Control Study. CC Craniocaudal and MLO mediolateral oblique.
Study MBCFS Mayo VTE




Age, mean (SD) (years) 57.2 (11.6) 61.0 (12.7)
BMI, mean (SD) (kg/m2) 27.1 (5.7) 28.4 (6.1)
Pre‑menopausal (%) 30.4 25.6
Percent density, mean 
(SD)
26.6 (15.91) 14.6 (13.62)




Digitizer Software Lumiscan Array 2905
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deleted CNV regions at 3q26.1 that were associated 
with PD in MBCFS. These two regions were separated 
by a segment defined by four probes that contains both 
insertions and deletions (Figure 2a). The 8q24.22 region 
consisted of 6 probes that were significantly associated 
with PD in MBCFS (Figure  1b). This region contains 
two genes: HHLA1 and OC90. Upon closer examination 
of the LRR values, it appears that a single probe (SNP) 
Table 2 CNV Regions identified in discovery phase (MBCFS) and evaluated in replication cohort (Mayo VTE)
MBCFS Mayo Breast Cancer Family Study and Mayo VTE Mayo Venous Thromboembolism Case–Control Study.
a Significant associations defined as p < 0.0001 for discovery phase and p < 0.05 for replication.
Chromosome Start position End position Number significant probesa
MBCFS (discovery) Mayo VTE (replication)
3 163,995,377 164,008,284 17 1
3 164,030,569 164,108,060 13 0
8 133,134,063 133,144,009 6 0
11 11,779,614 11,780,713 17 0
17 47,649,105 47,667,700 3 3
Figure 1 Candidate CNVs and SNP associations with PD in the Mayo Breast Cancer Family Study (MBCFS) for a 3q26.1 [2 regions], b 8q24.22,  
c 11p15.3 and d 17q22. For identifying candidate CNVs that are associated with PD, we performed probe‑specific tests and subsequently performed 
segmentation on the test‑statistics. P values were computed from permutation tests and were based on how many times the observed test‑
statistic, exceeded the permutation test statistics (using 10,000 permutations). Red circles denote CNV probes, black dots denote SNPs, the blue line 
denotes recombination rate, green lines denote genes, and the grey shaded areas denote the CNV region that was observed in MBCFS.
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was driving the association results (Figure  2b). How-
ever, while there are SNPs in this region, none were sig-
nificantly associated with PD (Figure  1b). The 11p15.3 
region consisted of 17 probes that were significantly 
associated with PD in MBCFS (Figure  1c). These 17 
probes defined a deleted region on 11p15.3 (Figure 2c). 
And, while there were SNPs in this region, none were 
significantly associated with PD (Figure  1c). The 17q22 
region consisted of three probes that were significantly 
associated with PD in MBCFS (Figure 1d). In contrast to 
the other regions, the 17q22 region had SNPs that were 
significantly associated with PD; the most significant 
SNP was rs12936458 (p value =  0.00023). After adjust-
ing for rs12936458, the CNV probes were no longer 
associated with PD. 
The Mayo VTE controls were used for replication. Sim-
ilar quality-control exclusions were made for the Mayo 
VTE controls, resulting in 328 individuals being analyzed 
(Table 1; Additional file 2). As demonstrated by Figure 3, 
the Mayo VTE controls showed similar CNVs for the two 
regions at 3q26.1 (Figure  3a) and the region at 11p15.3 
(Figure  3c) as was observed in MBCFS. Alternative 
Figure 2 LRR values from the Mayo Breast Cancer Family Study (MBCFS) for a 3q26.1 [2 regions], b 8q24.22, c 11p15.3, and d 17q22. Each row 
represents a sample and each column represents a probe.
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versions of these figures for both studies are shown 
in Additional files 4, 5, 6 and 7. While the CNVs were 
observed across the two datasets, we did not observe an 
association with PD in MBCFS. Specifically, only one 
probe at 3q26.1 showed a significant association with PD 
in the Mayo VTE controls (p < 0.0001 Table 2; Additional 
file 8); however, the coefficient was of the opposite direc-
tion (Additional file 9).
As mentioned previously, the two 3q26.1 regions are in 
an area on the Illumina 660W Quad array that only con-
tained CNV probes (there were no SNPs in this region; 
Figure 1a), suggesting that this is a known CNV region. 
This was confirmed by the absolute, inter-valued copy 
number estimates for 450 HapMap samples obtained 
from the Genome Structural Variation Consortium CNV 
discovery project, where chromosome 3 (163,994,833–
164,109,307) is listed [9]. This particular region showed 
54 (30%) CEU HapMap samples with deletions (18 with 
zero copies, 36 with one copy) and 60 (34%) samples 
with insertions. Thus, using PennCNV thirty-four probes 
in this region were used to force a CNV call in both the 
MBCFS and Mayo VTE samples. Within MBCFS there 
Figure 3 LRR values from the Mayo VTE control samples for a 3q26.1 (2 regions), b 8q24.22, c 11p15.3, and d 17q22. Each row represents a sample 
and each column represents a probe.
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were 181 (31%) samples with deletions (54 with zero 
copies, 127 with one copy) and 13 (2%) samples with 
insertions. The number of deletions was similar to those 
detected in the HapMap samples; however, the insertions 
were significantly less frequent in the MBCFS cohort. 
Comparison of samples with a deletion versus those 
without a deletion in MBCFS was significantly associ-
ated with PD (p = 0.005). The Mayo VTE control samples 
were used for replication: 10 (3%) subjects had deletions 
(three with zero copies, seven with one copy) and no 
samples had an insertion. Thus, the Mayo VTE controls 
did have similar number of deletions and insertions and 
we did not observe a significant association with PD.
Discussion
Prior reports have demonstrated that PD is a heritable 
trait; however, to date, only a small percentage of PD 
variation is explained by SNPs. To determine whether 
CNVs account for some of the remaining variability we 
conducted the first analysis of CNV and PD using two 
previously-published GWAS datasets. In the discovery 
set (MBCFS) we identified five candidate regions that 
were significantly associated with PD: 3q26.1 [2 regions], 
8q24.22, 11p15.3 and 17q22.
A CNV at 3q26.1 (163,698,399 to 163,718,292 in 
GRCh36/hg18; near the one we identified in the present 
study) has been previously reported to be associated with 
breast cancer risk in a Japanese population, though the start 
and end positions are slightly different [23]. We observed 
two CNVs at this region in both MBCFS and Mayo VTE 
control samples. However, only a single probe in the 3q26.1 
region was observed to be associated in the Mayo VTE rep-
lication samples and the effect was in the opposite direc-
tion. This discrepancy could be due to the fact that the two 
datasets had different study designs (MBCFS is a family 
study and the Mayo VTE controls were obtained from a 
case–control study) and/or because the PD distributions 
are different across the two studies. Because the CNV 
region replicates and because an association with breast 
cancer risk has been previously reported [23], we suggest 
that further investigation needs to be undertaken to fur-
ther try to replicate the result observed in MBCFS. Notably, 
neither the CNV region identified in the Japanese study or 
our study mapped to a gene [34, 35]. Lastly, it is important 
to note that the 3q26.1 regions would not be detected via 
GWAS analysis using the Illumina 660  W-Quad because 
there are no known SNPs in this region.
The 8q24 region has been shown to be associated with risk 
of many cancers, including breast, [36–42]. While our algo-
rithm detected a CNV at 8q24.22 that was associated with 
PD in the MBCFS samples, we were not able to replicate the 
results in Mayo VTE. Furthermore, upon further evaluation 
of the data, it appears that the results are largely being driven 
by a single probe. Even so, because the 8q24 region has been 
previously reported, we suggest that further investigation 
should be undertaken to replicate these results.
Our algorithm identified a CNV at 11p15.3 in MBCFS, 
which was validated in the Mayo VTE samples. However, 
we only observed a significant association with PD in the 
MBCFS samples. To our knowledge, this region has not 
been identified previously.
A CNV region at 17q22 was identified to be signifi-
cantly associated with PD in MBCFS. However, we deter-
mined that the association between this region and PD 
was driven by known SNPs in the region. Particularly, 
after adjusting for the most significant SNP in this region 
(rs12936458) the CNV was no longer associated with PD. 
Even so, the 17q22-23 region has previously been impli-
cated in breast cancer risk, and also has been shown to 
have copy number abnormalities and amplification in 
breast cancer cell lines and tumors [43–45]. Addition-
ally, CNVs significantly associated with breast cancer 
risk have been previously reported in the adjacent 17q21 
region, at BRCA1 [18, 20]. Therefore, additional examina-
tion of 17q21-23 may elucidate the role of CNVs in breast 
cancer pathogenesis.
Our analysis approach involved performing statisti-
cal association tests on the probe-level data and subse-
quently performing segmentation on the probe-level 
test statistics to identify candidate regions that are asso-
ciated with PD [46]. Our approach is different from the 
majority of CNV analyses where candidate CNVs are 
first identified for each sample, the candidate CNVS 
are subsequently grouped together to create consen-
sus regions across all samples, and lastly, the consensus 
regions are tested for associations with the trait of inter-
est [47–49]. There are at least two problematic aspects of 
this approach. First, there are numerous CNV detection 
algorithms available and unfortunately, the consensus of 
these algorithms is very low [40]. Second, it is not a trivial 
task to define consensus regions across individuals. Thus, 
the strength of the approach used herein is that it avoids 
the variability associated with both identifying candi-
date CNV regions and defining common CNV regions 
across individuals. Motivation for our approach is shown 
in simulations presented by Breheny, who found that 
probe-level testing can offer a significant increase (>12-
fold) in power over traditional CNV-level testing [46]. 
We acknowledge that probe-level testing can be com-
putationally intensive; however, we minimized this issue 
by performing segmentation only in those regions where 
there was some indication of a statistical association. A 
potential weakness with our approach, as shown by Bre-
heny, is that it may not perform as well when CNV are 
large and rare. Additionally, our approach is not as sen-
sitive when there are duplications and insertions at the 
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same location. These limitations notwithstanding, our 
probe-level testing approach identified candidate CNVs 
that were evident in both datasets, as shown in Figure 2.
Conclusion
In summary, we identified five candidate CNV regions 
[3q26.1 (2 regions), 8q24.22, 11p15.3 and 17q22] that 
showed evidence of an association with PD. While 
three of CNV regions were observed in a second dataset 
[3q26.1 (2 regions), 11p15.3], we were unable to repli-
cate the associations with PD. However, these CNVs have 
been previously implicated in breast cancer risk as well as 
other malignancies. Thus, there is a possibility that they 
did not replicate in the Mayo VTE samples because of the 
different experimental design, power and/or the different 
PD measurements. As such, we recommend additional 
investigations to further examine these CNVs with PD 
and breast cancer in other populations to better under-
stand genetic mechanisms by which PD may influence 
breast cancer risk.
Additional files
Additional file 1: CNV analysis procedure. This flowchart represents the 
steps that were used to identify candidate CNV regions that are associated 
with PD.
Additional file 2: Study‑specific genotyping details for discovery 
(MBCFS) and replication (Mayo VTE).
Additional file 3: 48 candidate regions were identified in the data 
reduction step of the analysis (described in Supplementary Figure 1). Sub‑
sequently, five regions were identified as having a statistically‑significant 
association with percent density in MBCFS.
Additional file 4: LRR values from the Mayo Breast Cancer Family Study 
(MBCFS) and the Mayo VTE control samples for 3q26.1 [2 regions]. Each 
line represents a sample and the colors represent different CNV patterns.
Additional file 5: LRR values from the Mayo Breast Cancer Family Study 
(MBCFS) and the Mayo VTE control samples for 8q24.22. Each line repre‑
sents a sample and the colors represent different CNV patterns.
Additional file 6: LRR values from the Mayo Breast Cancer Family Study 
(MBCFS) and the Mayo VTE control samples for 11p15.3. Each line repre‑
sents a sample and the colors represent different CNV patterns.
Additional file 7: LRR values from the Mayo Breast Cancer Family Study 
(MBCFS) and the Mayo VTE control samples for 17q22. Each line repre‑
sents a sample and the colors represent different CNV patterns.
Additional file 8: Candidate CNVs and SNP associations with PD for the 
two regions that had significant associations in the Mayo VTE samples: (A) 
3q26.1 [2 regions] and (B) 17q22.  For validating the candidate CNVs that 
were found to be associated with PD in the MBCFS study, we performed 
probe‑specific tests and subsequently performed segmentation on the 
test‑statistics in the Mayo VTE samples. P‑values were computed from 
permutation tests and were based on how many times the observed test‑
statistic, exceeded the permutation test statistics (using 10,000 permuta‑
tions). Red circles denote CNV probes, black dots denote SNPs, the blue 
line denotes recombination rate, green lines denote genes, and the grey 
shaded areas denote the CNV region.
Additional file 9: Coefficients and permutation based p‑values for 
chromosome 3 and 17 using the discovery (MBCFS) and replication (Mayo 
VTE) cohorts.
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